Implementation analysis highlights determinants for long-acting injectable cabotegravir-rilpivirine in virally unsuppressed HIV, indicating a need for guided delivery strategies.
Early evidence suggests long-acting injectable cabotegravir and rilpivirine (LA-CAB/RPV) may be beneficial for people with HIV (PWH) who are unable to attain viral suppression (VS) on oral therapy. Limited guidance exists on implementation strategies for this population.
No takes yet. Share an insight, caveat, or question.
Hickey et al. (2024) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: